MFDS Tightens Clinical Trial Guidelines for Digital Therapeutics
This regulatory shift impacts digital therapies designed for nicotine use disorder, alcohol use disorder, panic disorder, depressive disorder, eating disorders, attention deficit hyperactivity disorder (ADHD), and mild cognitive impairment. Software-based … Read More